Principal Securities’s Maravai LifeSciences MRVI Stock Holding History

Principal Securities’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-48	Closed	-$138	–	2692
2025 Q3	$138	Buy	+48	New	+$123	﹤0.01%	3676

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Securities's MRVI Position: Q4 2025 in Review

Principal Securities sold out of Maravai LifeSciences (MRVI) in Q4 2025, closing a stake of 48 shares — an estimated $138 sold.

Principal Securities first reported a position in MRVI in Q3 2025 and held it in 1 quarter. The position peaked at $138 in Q3 2025. 159 funds tracked by Wall St. Rank hold MRVI as of Q4 2025.

Principal Securities reported no remaining Maravai LifeSciences position as of Q4 2025 after selling out during the quarter.
Principal Securities sold 48 Maravai LifeSciences shares in Q4 2025, an estimated $138.
Principal Securities first reported a position in Maravai LifeSciences in Q3 2025 and held it in 1 quarter.
Principal Securities's Maravai LifeSciences position peaked at $138 in Q3 2025.
159 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.